| Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data I Tomazos, AJ Hatswell, S Cataland, P Chen, N Freemantle, Å Lommele, ... Clinical Nephrology 97 (5), 261, 2022 | 16 | 2022 |
| Cost-effectiveness analysis of rFVIIIFc versus contemporary rFVIII treatments for patients with severe hemophilia A without inhibitors in the United States A Bullement, ES Knowles, P DasMahapatra, T Ali, R Preblick PharmacoEconomics-Open 5, 625-633, 2021 | 6 | 2021 |
| An Economic comparison of treatment strategies with anakinra in systemic Juvenile Idiopathic Arthritis (sJIA) A Bullement, ES Knowles, M Langenfeld, GR Diogo, J Nazir, D Eriksson Open Access Rheumatology: Research and Reviews, 257-266, 2021 | 3 | 2021 |
| 1255P Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) N Reinmuth, S Popat, L Paz-Ares, E Knowles, A Hatswell, T McLean, ... Annals of Oncology 32, S985-S986, 2021 | 2 | 2021 |
| Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping M Yang, H Vioix, ES Hook, AJ Hatswell, RL Batteson, BR Gaumond, ... Value in Health 26 (8), 1155-1163, 2023 | 1 | 2023 |
| CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) A Hatswell, R Batteson, E Hook, H Wheat, H Vioix, T McLean, ... Value in Health 25 (12), S21-S22, 2022 | 1 | 2022 |
| CO94 Tepotinib Compared With Chemoimmunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC): Matching Adjusted Indirect Comparison (MAIC) of VISION in MET Exon 14 (METex14 … H Vioix, A Hatswell, T McLean, C Day, R Batteson, E Hook, S Alexopoulos, ... Value in Health 25 (12), S36, 2022 | 1 | 2022 |
| RWD51 Demonstrating Internal and External Validity in Real-World Datasets: A Case Study in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) R Batteson, E Hook, H Vioix, A Hatswell Value in Health 25 (12), S458, 2022 | 1 | 2022 |
| Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring MET ex14 Skipping … R Batteson, E Hook, H Wheat, AJ Hatswell, H Vioix, T McLean, ... Targeted Oncology, 1-11, 2024 | | 2024 |
| SA22 Tepotinib Versus Chemotherapy in Met Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence (RWE) and Matching-Adjusted Indirect Comparison … H Wheat, A Hatswell, P Christopoulos, S Ekman, F Guisier, E Hook, ... Value in Health 26 (12), S545, 2023 | | 2023 |
| CO168 A Propensity Score-Based Comparison of Tepotinib Versus Immunotherapy with/without Chemotherapy, Using Real-World Data in Previously Untreated Met Exon 14 (METEX14 … E Hook, R Batteson, P Christopoulos, F Guisier, S Ekman, A Hatswell, ... Value in Health 26 (12), S44, 2023 | | 2023 |
| De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation P Gal, G Feldmajer, M Augusto, R Gani, E Hook, A Bullement, Z Philips, ... PharmacoEconomics 41 (12), 1629-1639, 2023 | | 2023 |
| EE146 Cost-effectiveness of Tepotinib for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Harboring Metex14 Skipping Alterations in Spain E Arriola, R Batteson, E Hook, H Wheat, H Vioix, M Morros, M Águila, ... Value in Health 26 (6), S86, 2023 | | 2023 |
| PCR153 A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC … E Hook, H Vioix, R Batteson, T McLean, A Hatswell Value in Health 25 (12), S420, 2022 | | 2022 |
| EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) Harboring MET Exon 14 (METex14) Skipping T McLean, S Alexopoulos, E Hook, R Batteson, H Vioix Value in Health 25 (12), S143, 2022 | | 2022 |
| A UK cost–effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers L Hamerton, K Gomes, R Fougeray, ES Hook, MV Gomes, O Hauch, ... Future Oncology 19 (9), 643-650, 2022 | | 2022 |
| US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib PK Paik, M Yang, E Knowles, A Hatswell, H Vioix, FX Liu Journal of Clinical Oncology 39 (28_suppl), 319-319, 2021 | | 2021 |
| AN ECONOMIC COMPARISON OF TREATMENT STRATEGIES WITH ANAKINRA IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) A Bullement, E Knowles, A van Leeuwen-Gorter, M Langenfeld, RG Diogo, ... VALUE IN HEALTH 23, S538-S538, 2020 | | 2020 |
| PIH4 An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (SJIA) A Bullement, E Knowles, A van Leeuwen-Gorter, M Langenfeld, GR Diogo, ... Value in Health 23, S539, 2020 | | 2020 |
